ARCH Venture Partners

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

City Therapeutics is a biopharmaceutical company specializing in the development of next-generation small-interfering RNAs (siRNAs) to enhance RNA interference (RNAi) therapies. The company's pipeline comprises innovative RNAi therapeutics targeting diverse disease indications. City Therapeutics aims to improve and expand RNAi technology to achieve better patient outcomes, led by a team of experienced scientists and industry professionals committed to advancing the field of RNA interference.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Metsera is a clinical-stage biopharmaceutical company specializing in developing innovative therapies for obesity and metabolic conditions. It focuses on advancing oral and injectable treatments, integrating proprietary health technology tools for personalized care.

Seaport Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel neuropsychiatric medicines in areas of high patient need. Its innovative approach aims to improve oral bioavailability, thereby reducing side effects such as hepatotoxicity and enhancing patients' quality of life with neuropsychiatric disorders.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Gate Bioscience is a biotechnology company focused on developing small molecule drugs aimed at treating challenging diseases by selectively eliminating harmful extracellular proteins at their source within cells. The company utilizes a unique library of molecular gates along with specialized secretion-focused assays and technologies, leveraging its deep understanding of the biology of the secretory pathway. This approach facilitates precise, rapid, and repeatable drug discovery, allowing for the potential to address a diverse array of diseases using a single therapeutic mechanism.

Lightcast Discovery Limited, founded in 2019 and based in Cambridge, United Kingdom, specializes in drug discovery through advanced microfluidic technology. The company focuses on developing new therapies and innovative products by leveraging its unique platform, which allows for the precise and flexible control of thousands of droplets. This capability enables the combination of various cells, reporters, and reagents to conduct complex workflows without manual cell manipulation. By collaborating with major pharmaceutical companies and leading academic institutions, Lightcast Discovery seeks to enhance complex cell analysis and facilitate the discovery of new clinical approaches.

Myeloid Therapeutics is an immunology company dedicated to leveraging innovative technologies to harness the potential of myeloid cells for the treatment of cancer and other diseases. The company has developed the ATAK platform, which focuses on reprogramming innate immune cells to enhance their ability to target and eliminate cancerous cells. Initially, Myeloid Therapeutics is advancing a cell therapy program aimed at treating T cell lymphoma, as well as a primed monocyte strategy for glioblastoma. The versatility of the ATAK platform allows for scalability across various treatment modalities and disease areas, facilitating collaboration with partners to expand its applications in the field of immunotherapy.

Orbital Therapeutics develops innovative RNA-based medicines to enhance global health. Its platform integrates RNA technology, delivery techniques, data analytics, and automation to create a broad portfolio of treatments for various diseases.

Rapport Therapeutics is a clinical-stage biotechnology company dedicated to discovering and developing precision medicines for neurological disorders. The company focuses on creating transformational small-molecule therapies aimed at patients with central nervous system conditions. Leveraging foundational research in neuronal receptor biology, Rapport Therapeutics maps and targets specific neuronal receptor complexes, which are complex assemblies of proteins that include principal receptor subunits and receptor-associated proteins. These receptor-associated proteins are essential for regulating receptor expression and functionality, allowing the company to innovate in the treatment of neurological diseases.

Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. It is an innovative company that is dedicated to transforming the clinical research ecosystem. Their mission is to create a more accessible and equitable healthcare system by developing a platform that enables patients from diverse backgrounds to participate in clinical trials. Clinical trials are essential for testing and developing new drugs, therapies, and medical devices, but historically, they have been plagued by inefficiencies, barriers to access, and inequities in patient representation. Paradigm aims to solve these challenges by creating a platform that uses technology and data-driven insights to streamline the clinical trial process, making it more efficient, cost-effective, and inclusive. The Paradigm platform is designed to facilitate seamless communication and collaboration among all stakeholders involved in clinical research, including patients, healthcare providers, pharmaceutical companies, and regulatory agencies. By leveraging technology such as AI, machine learning, and predictive analytics, Paradigm can identify and match eligible patients to clinical trials, streamline the recruitment and enrollment process, and provide real-time data insights to all stakeholders. Overall, Paradigm's innovative approach to clinical research has the potential to revolutionize the healthcare industry by improving patient outcomes, reducing healthcare costs, and accelerating the development of new treatments and therapies.

Protillion Biosciences is a biotechnology company focused on transforming therapeutic antibody and drug discovery through its innovative protein engineering platform. This high-throughput platform is designed to streamline and enhance traditional methods of designing and developing protein-based drugs. By utilizing advanced techniques, Protillion aims to accelerate the research and development process for biologics, thereby enabling healthcare professionals to discover and bring new protein therapeutics to market more efficiently. The company's commitment to developing disruptive technology positions it as a key player in the evolving landscape of drug discovery and development.

Human Immunology Biosciences is a biotechnology company dedicated to developing precision therapies for immune-mediated diseases, particularly autoimmune and inflammatory conditions. The company is known for its lead product, felzartamab, a fully human anti-CD38 monoclonal antibody that targets and depletes CD38+ cells, including plasma and natural killer cells. This mechanism has shown promise in improving clinical outcomes across a range of immune-mediated disorders. By focusing on transformative biotechnology-based treatments, Human Immunology Biosciences aims to enhance the quality of life for patients suffering from these challenging conditions.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Orbital Therapeutics develops innovative RNA-based medicines to enhance global health. Its platform integrates RNA technology, delivery techniques, data analytics, and automation to create a broad portfolio of treatments for various diseases.

Vilya is a biotechnology company focused on developing innovative drugs that precisely target the underlying biology of diseases. By leveraging advanced computational techniques, Vilya aims to create a new class of medicines that can efficiently navigate uncharted chemical spaces and generate novel molecular structures. These structures, which are designed to possess essential drug-like properties, can range in size between small molecules and antibodies. Vilya's platform is engineered to improve the drug discovery process, enabling more effective treatments by facilitating the disruption of protein-protein interactions and ensuring optimal movement through biological membranes. Through its pioneering approach, Vilya is dedicated to advancing therapeutic options for patients.

Founded in 2020, Be Biopharma specializes in developing innovative therapeutics using engineered B-cells to treat diseases such as cancer, autoimmune disorders, and infectious diseases. Its approach aims to overcome limitations of current cell and gene therapies.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

ONI specializes in super-resolution microscopy, making advanced imaging technology accessible to researchers worldwide. Its flagship product, the Nanoimager, offers easy access to techniques like dSTORM and PALM, enabling users to visualize molecules within living cells for enhanced biological research.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Mozart Therapeutics is a biotechnology company specializing in the development of disease-modifying therapies for autoimmune and inflammatory diseases. It focuses on creating first-in-class CD8 Treg modulators to restore long-term immune balance and prevent progressive damage caused by autoreactive immune responses.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Interline Therapeutics is a drug discovery company that maps and modulates protein communities to reveal molecular mechanisms of disease and develop precision medicines. Using genomics, proteomics, structural biology, and computational chemistry, it analyzes signaling networks to identify genetically validated targets and design therapies that comprehensively correct dysfunctional protein communities. The company is based in South San Francisco and was established in 2020.

Excision BioTherapeutics Inc. is a life science company based in Philadelphia, Pennsylvania, established in 2015. The company is dedicated to the development and commercialization of gene editing therapeutics aimed at treating life-threatening diseases caused by neurotropic viruses. Utilizing CRISPR-based technology, Excision BioTherapeutics focuses on creating advanced gene-editing medicines that can eradicate or disrupt viral genes in human patients. The company's mission is to advance these therapeutics into safe and effective treatments, significantly improving the lives of individuals affected by viral infections globally.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

SciNeuro Pharmaceuticals is a biotechnology company based in Shanghai, China, focused on developing innovative medicines for patients with central nervous system (CNS) diseases. The company is committed to transforming the treatment landscape for these conditions through a robust product pipeline that emphasizes internal innovation and global collaboration. SciNeuro's drug development is guided by breakthrough scientific evidence, including insights from human genetics and pharmacology, targeting the underlying mechanisms of CNS diseases. By addressing these pathological mechanisms, SciNeuro aims to provide transformative therapies that not only aim to cure these diseases but also enhance the quality of life for patients.

National Resilience, also known as Resilience, is a biopharmaceutical manufacturing and technology company that provides end-to-end manufacturing and development solutions for diverse modalities, including cell and gene therapies, viral vectors, vaccines, and proteins. It actively invests in developing new manufacturing technologies to expand access to complex medicines and supports partners through the full lifecycle from development to commercial supply. The company was incorporated in 2020 and is based in La Jolla, California.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

Founded in 2018 and headquartered in Boston, Massachusetts, Dewpoint Therapeutics is a biotechnology company dedicated to researching biomolecular condensates and cellular function. The company aims to develop innovative treatments for various diseases such as cancer, neurodegenerative disorders, immunology, cardiovascular conditions, women's health, and virology.

Autobahn Therapeutics develops brain-targeting, small molecule therapies for central nervous system disorders. Its lead program ABX-002 is a thyroid hormone receptor beta agonist being developed as an adjunctive treatment for mood disorders, including major depressive disorder and bipolar depression. The company emphasizes precision tuning of CNS exposure, validated clinical and biologic targets, and biomarker-guided development across neuropsychiatry, neurodegeneration, and neuroinflammation to address high unmet medical needs and improve patient outcomes.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Erasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company's pipeline includes Naporafenib, ERAS-007, and ERAS-601, targeting various nodes of this pathway.

CERo Therapeutics is a biotechnology company focused on cellular immunotherapy and next-generation engineered T cell therapeutics for cancer. It develops platforms that integrate innate and adaptive immune programs to enhance anti-tumor activity and engage the body's full immune repertoire. The company was incorporated in 2016 and is headquartered in San Francisco, California. Its lead product, CER-1236, is an autologous T-cell therapy targeting a novel tumor antigen, TIM-4 ligand.

Sonoma Biotherapeutics, Inc. is focused on developing adoptive T regulatory (Treg) cell therapies aimed at treating autoimmune and degenerative diseases. Established in 2019 and based in South San Francisco, California, with an additional office in Seattle, the company employs next-generation genome editing and target-specific cell therapy techniques to innovate in the field of Treg cell therapeutics. The firm aims to create disease-modifying and potentially curative therapies that promote self-tolerance and inhibit harmful inflammatory responses associated with conditions such as rheumatoid arthritis, inflammatory bowel disease, multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer's disease. Founded by experts in Treg biology and cell therapy, Sonoma Biotherapeutics integrates advanced methodologies to enhance its therapeutic offerings.

EQRx, Inc. is a biotechnology company based in Cambridge, Massachusetts, established in 2019. The company focuses on re-engineering the drug discovery and delivery process to provide a market-based solution to the escalating costs of medications. EQRx aims to enhance the efficiency and affordability of high-quality, patent-protected medicines by collaborating with various stakeholders across the healthcare system and leveraging advancements in science and technology. The company has developed a robust pipeline with over ten programs, including clinical and preclinical projects targeting oncology and immune-inflammatory conditions, featuring compounds such as Aumolertinib, Lerociclib, Sugemalimab, and Nofazinlimab.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Epirium Bio, Inc. is a biopharmaceutical company based in San Diego, California, focused on developing therapeutics for cardiovascular diseases, metabolic syndrome, and disorders characterized by mitochondrial dysfunction. Founded in 2008, the company leverages unique insights into mitochondrial biology and tissue regeneration to create a small molecule platform aimed at improving muscle strength and facilitating tissue regeneration. Epirium Bio's innovative approach addresses significant clinical needs in treating neuromuscular, neurodegenerative, and mitochondrial disorders, enabling healthcare providers to better support patients suffering from conditions such as muscular dystrophy.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Boundless Bio develops innovative cancer therapeutics focused on understanding and treating previously untreatable cancers. It specializes in targeting extrachromosomal DNA (ecDNA) biology, a key driver of aggressive cancers.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

LunaPBC, Inc. is a Public Benefit Corporation based in San Diego, California, focused on developing a community-owned platform for health and DNA research. The company's primary offering is LunaDNA, a genomic and medical research knowledge database that enables individuals to share their health and DNA data for research purposes. This platform facilitates collaborations with pharmaceutical companies, insurance providers, and healthcare IT organizations to drive advancements in medical discoveries. By allowing members to contribute their health data, LunaPBC not only supports vital health research projects but also ensures that participants can share in the financial benefits arising from medical breakthroughs, fostering a sense of community ownership and engagement in the research process.

Verve Therapeutics is a biotechnology company developing genetic medicines for cardiovascular disease, aiming to transform treatment from chronic management to single-course gene editing therapies. It leverages human genetics analysis and gene-editing technology, with expertise in cardiovascular medicine, human genetics, gene editing, delivery technologies, drug development, and commercialization.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Erasca is a clinical-stage precision oncology company dedicated to discovering and developing therapies for patients with cancers driven by the RAS/MAPK pathway. Founded in 2018, the company's pipeline includes Naporafenib, ERAS-007, and ERAS-601, targeting various nodes of this pathway.

Founded in 2019, HiberCell is a biotechnology company based in New York. It develops therapeutics focused on preventing cancer relapse and metastasis by targeting adaptive stress pathways and immune modulation.

Transcenta Holding is a clinical-stage biopharmaceutical company that offers fully integrated capabilities in antibody discovery, research and development, manufacturing, and business development. The company concentrates on developing innovative antibody-based therapeutics for oncology and selected non-oncology indications, including bone and kidney disorders, with a pipeline that includes Osemitamab (TST001), TST002, TST003, TST006, MSB2311, MSB0254, TST808, and other candidates. Headquartered with multiple sites in China—Suzhou, Shanghai, Hangzhou, and Beijing—and with research and development and operations in the United States at Waltham and Princeton, Transcenta operates as a global biotherapeutics business. Founded in 2019, the company aims to advance therapeutic antibodies through discovery, development, and manufacturing to address unmet patient needs. Its business scope encompasses clinical research and trial services alongside its development programs, positioning it to accelerate pipeline progress and collaborate on global opportunities.

Magnolia Neurosciences Corporation is a New York-based company focused on drug discovery and development, specifically targeting neuroprotective therapies for central nervous system diseases and neurodegeneration. Established in 2018, the company aims to create proprietary small molecule therapeutics that prevent neuronal cell death, offering new treatment options for patients with neurodegenerative disorders and related conditions. Magnolia Neurosciences was founded to advance technologies developed at The University of Texas MD Anderson Cancer Center’s Therapeutics Discovery Division and the Neurodegeneration Consortium. Through its innovative approach, the company seeks to address significant medical needs in the field of neurology.

Karuna Therapeutics is a biopharmaceutical company dedicated to developing innovative treatments for psychiatric and neurological disorders. Its primary focus is on creating novel therapies to address disabling neuropsychiatric conditions, with a particular emphasis on schizophrenia and the behavioral symptoms of Alzheimer's disease.

Qihan Biotech is a biomedical company specializing in genetic technology with a focus on addressing the global shortage of organ donors. The company aims to produce safe and effective cells, tissues, and organs for human transplantation using advanced gene editing techniques. By applying these technologies to xenogenic organ transplantation, Qihan Biotech seeks to create organs that can be transplanted into humans, thereby reducing the need for traditional organ transplants and saving lives.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Founded in 2018, Brii Biosciences is a biotechnology company dedicated to researching, developing, and commercializing medicines for chronic illnesses, with a primary focus on infectious diseases. Headquartered in Durham, North Carolina, the company operates additional offices in Shanghai and Beijing, China; and San Francisco, California.

CStone Pharmaceuticals, founded in 2015, focuses on developing and commercializing innovative immunotherapy and precision treatment drugs for cancer patients worldwide. Its pipeline comprises over a dozen candidates targeting various indications, with immuno-oncology at its core.

Insitro, Inc. is a data-driven company focused on drug discovery and development, particularly targeting nonalcoholic steatohepatitis (NASH). Founded in 2018 by Daphne Koller and based in South San Francisco, California, Insitro harnesses machine learning and high-throughput biology to revolutionize the process of drug discovery. The company creates extensive functional genomic data sets and integrates them with patient data through innovative machine learning techniques. This approach allows Insitro to build predictive models that enhance target selection, streamline the design of therapeutics, and optimize drug development strategies. By addressing critical challenges in pharmaceutical research and development, Insitro aims to accelerate the delivery of new and effective treatments to patients.

Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that specializes in the discovery, development, and commercialization of innovative therapeutic products targeting significant unmet medical needs. Founded by former executives from Receptos, the company focuses on areas such as immunology, inflammation, fibrosis, and oncology. Its pipeline includes several promising candidates: Seralutinib, aimed at addressing pulmonary arterial hypertension; GB004, for inflammatory bowel disease; GB1275, targeting various oncology indications; and GB001, designed for moderate-to-severe eosinophilic asthma. Gossamer Bio's strategy involves leveraging a rich in-licensing environment to enhance its therapeutic offerings, supported by a team recognized for their successful track record in drug development.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

ImmusanT, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing therapies and diagnostics for celiac disease. Founded in 2010, the company aims to restore immune tolerance to gluten in patients with this autoimmune disorder. Its primary product, Nexvax2, is a therapeutic vaccine designed to treat, prevent, and diagnose celiac disease. Additionally, ImmusanT is working on a functional T-cell test to facilitate the diagnosis and monitoring of immune tolerance in patients undergoing peptide-based therapy. Through its innovative approach, the company seeks to enhance the management of celiac disease and potentially other autoimmune conditions.

LifeMine Therapeutics, Inc. is a biotechnology company focused on the genomic discovery of new drug modalities derived from eukaryotic microbes, specifically fungi. Founded in 2016 and headquartered in Cambridge, Massachusetts, with an additional office in New York, it employs an integrated drug discovery platform that combines genomics, artificial intelligence, and synthetic biology. LifeMine’s Avatar-Rx platform utilizes high-throughput microbiology, data science, genome engineering, and automation technologies to identify novel gene-encoded molecules (GEMs) with specific biological functions. The company emphasizes chemoinformatic-assisted drug optimization and advanced chemical synthesis, enabling the progression of new product candidates into development. Founded by experts in the field, LifeMine Therapeutics aims to innovate medicine through its unique approach to leveraging the fungal biosphere.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

ApoGen Biotechnologies, Inc. is a biotechnology company based in Seattle, Washington, established in 2014. The company specializes in developing innovative therapeutics aimed at addressing the challenges of drug resistance in cancer treatment. Recognizing that the mutation of cellular DNA is central to cancer progression, ApoGen focuses on therapies that target key drivers of genomic mutations and tumor evolution. By doing so, the company aims to slow or halt the ongoing mutations within cancer genomes, which are significant contributors to treatment failure, cancer recurrence, and metastasis. Through its advanced therapeutic approaches, ApoGen Biotechnologies seeks to improve outcomes for patients facing the complexities of cancer evolution and drug resistance.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Blackthorn Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in South San Francisco, California, founded in 2013. The company focuses on developing precision medicine for neurobehavioral disorders, utilizing advances in computational and clinical neuroscience. By leveraging its proprietary computational platform, Blackthorn aims to address historical challenges in drug discovery by targeting dysfunctional brain circuits. This approach enables the identification of novel drug candidates and biologically-based patient subgroups that are most likely to respond to specific treatments. Through its innovative strategies, Blackthorn seeks to enhance the precision of therapeutic interventions for disorders of the central nervous system, ultimately improving patient outcomes.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

VBI Vaccines Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, with research facilities in Ottawa, Canada. It develops and sells vaccines for infectious diseases and immuno-oncology, with a focus on expanding protection in large, underserved markets. The company's enveloped virus-like particle (eVLP) platform enables the creation of vaccines that closely mimic target viruses, eliciting potent immune responses. VBI's commercial product, Sci-B-Vac, is a hepatitis B vaccine approved in Israel and 14 other countries, offering rapid onset of protection and high antibody levels. The company is also developing VBI-2601 for a functional cure of chronic hepatitis B, VBI-1901 for glioblastoma, and VBI-1501 for cytomegalovirus, among other candidates. VBI collaborates with pharmaceutical companies and research institutions, and its products are primarily distributed through direct sales to physicians and pharmacists.

Homology Medicines is a biotechnology company focused on developing genetic therapies for rare diseases. Its proprietary platform uses human hematopoietic stem cell-derived adeno-associated virus vectors to deliver treatments in vivo, targeting various tissues including the liver and central nervous system. The company's lead product candidate, HMI-102, is in clinical trials for treating phenylketonuria.

Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

GRAIL focuses on developing technologies for early cancer detection. Founded in 2016, the company specializes in a pan-cancer screening test that measures circulating nucleic acids in blood using high-intensity sequencing.

Lodo Therapeutics Corporation is a drug discovery and development company dedicated to creating novel therapeutics derived from natural sources. It focuses on addressing significant health challenges, particularly resistant infectious diseases and cancers, by collaborating with global pharmaceutical companies and leading non-governmental organizations. Founded to realize the scientific vision of Dr. Sean Brady from Rockefeller University, Lodo Therapeutics utilizes a genome-based, culture-independent platform to discover and characterize small molecules sourced from environmental microbial DNA. This innovative approach leverages advancements in DNA sequencing and bioinformatics to explore the untapped potential of microbial evolution, aiming to identify therapeutically valuable pharmaceutical products. Headquartered in New York City at the Alexandria Center for Life Science, Lodo Therapeutics is committed to harnessing the power of nature in the fight against undruggable targets and high unmet medical needs.

Petra Pharma Corporation is a clinical-stage pharmaceutical company based in New York, focused on discovering and developing innovative therapies that modulate phosphoinositide (PI) signaling pathways for the treatment of cancer and metabolic diseases. Founded in 2015, the company targets novel enzyme pathways that play crucial roles in various cellular processes, such as cell division, growth, trafficking, and signaling. By developing small molecules aimed at these processes, Petra Pharma seeks to create impactful therapeutic options that enhance patient care and improve health outcomes.

Codiak BioSciences is a clinical-stage biopharmaceutical company dedicated to developing exosome-based therapeutics, a novel class of medicines with the potential to address various diseases with significant unmet medical needs. The company employs its proprietary engEx Platform, which allows for the engineering and manufacturing of exosomes, leveraging their natural role as intercellular messengers. Codiak's pipeline includes product candidates such as exoSTING and exoIL-12, targeting diverse therapeutic areas including oncology, neuro-oncology, neurology, neuromuscular diseases, and infectious diseases. Additionally, the company collaborates with the Ragon Institute to explore the potential of its exoVACC platform for vaccines against SARS-CoV-2 and HIV. Founded in 2015 and headquartered in Cambridge, Massachusetts, Codiak aims to transform therapeutic approaches by harnessing the unique properties of exosomes.

Hangzhou Just Biotherapeutics, also known as Just China, is a biotechnology company based in Hangzhou, China, that specializes in the development of antibody and recombinant protein biotherapeutics. Founded in 2016, the company focuses on leveraging its expertise in molecular design, process design, and drug product design to facilitate the development of biologics. By employing advanced protein, process, and manufacturing sciences, Hangzhou Just Biotherapeutics aims to overcome technical challenges associated with protein therapeutics, thereby accelerating development timelines and significantly lowering manufacturing costs. As a subsidiary of MabSpace Biosciences Co., Ltd., the company positions itself as a key player in the biopharmaceutical sector, dedicated to enhancing the efficiency of biomedical innovation.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

Metacrine, Inc. is a clinical-stage biopharmaceutical company based in San Diego, California, established in 2014. It specializes in the discovery and development of innovative therapies aimed at treating liver and gastrointestinal diseases. The company is advancing a pipeline of drug candidates, with a primary focus on the farnesoid X receptor (FXR), a key target in managing various liver and GI disorders. Its lead candidates, MET409 and MET642, are currently in clinical trials to evaluate their efficacy in treating non-alcoholic steatohepatitis. Additionally, Metacrine collaborates with Novo Nordisk A/S to explore further research opportunities related to fibroblast growth factor 1. The company is committed to developing best-in-class therapies to improve patient outcomes in these challenging medical areas.

Pulmatrix is a clinical-stage biopharmaceutical company developing inhaled therapies to address serious pulmonary diseases using its patented iSPERSE technology. Its pipeline focuses on Pulmazole, an inhaled anti-fungal for allergic bronchopulmonary aspergillosis, and PUR1800, a narrow spectrum kinase inhibitor for obstructive lung diseases like asthma and COPD.

Denali Therapeutics is a biopharmaceutical company dedicated to discovering and developing therapies for neurodegenerative diseases such as Alzheimer's, Parkinson's disease, and amyotrophic lateral sclerosis (ALS). The company is advancing several therapeutic candidates, including LRRK2 inhibitors like DNL201 and DNL151 for Parkinson's disease, and DNL747, a RIPK1 inhibitor targeting Alzheimer's and ALS. Denali's innovative approaches also include enzyme replacement therapy for MPS II and antibody transport vehicle programs aimed at addressing alpha-synuclein and Tau pathology. Established in 2013 and headquartered in South San Francisco, California, Denali collaborates with notable organizations including Takeda, Genentech, and the Michael J. Fox Foundation to leverage research and development in the field of neurodegeneration. The company aims to translate scientific insights into effective treatments, contributing to the ongoing effort to combat these debilitating conditions.

Kura Oncology is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for cancer patients. Its pipeline comprises small molecule drug candidates targeting specific cancer signaling pathways, with a focus on solid tumors and hematologic malignancies.

Chiasma is a biopharmaceutical company specializing in late-stage clinical development. It focuses on transforming injectable drugs into oral medications using its proprietary Transient Permeability Enhancer technology, with a primary focus on treating rare and serious chronic diseases.

Hua Medicine is a clinical-stage drug development company in China focused on therapies for diabetes and CNS disorders. It develops Dorzagliatin (also known as HMS5552), an oral, first-in-class glucokinase activator for type 2 diabetes, and has advanced Dorzagliatin into NDA-enabling work and Phase III trials in China, including studies in drug-naive and metformin-treated patients. The company is pursuing Dorzagliatin in combination with metformin and in combination with DPP-4 inhibitors, SGLT-2 inhibitors, and insulin in various development stages. In addition, Hua Medicine is developing mGluR5 candidates for Parkinson's disease and related levodopa-induced dyskinesia. The company was founded in 2011 and is headquartered in Shanghai, China.

Unity Biotechnology is a biotechnology company dedicated to developing therapeutics that prevent, halt, or reverse age-related diseases. Its primary focus involves targeting senescent cells, designing senolytic medicines to clear these cells from the body while leaving normal cells unaffected. The company's pipeline includes UBX1325 for age-related eye diseases like diabetic macular edema.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

VentiRx Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company based in Seattle, Washington, founded in 2006. The company specializes in developing and commercializing immunotherapies that target Toll-like Receptor 8 (TLR8) for the treatment of cancer, respiratory, and inflammatory diseases. Its lead investigational drug, Motolimod, aims to activate the immune system by stimulating myeloid dendritic cells, monocytes, and natural killer cells to combat cancer. VentiRx's product pipeline includes VTX-2337, a small molecule TLR8 agonist targeting solid tumors and various cancers, as well as VTX-1463 for treating allergies. The company also explores TLR8 antagonists for autoimmune diseases and other compounds that may serve as vaccine adjuvants. VentiRx has a strategic collaboration with Celgene Corporation to further its research and development efforts.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell-based immunotherapies for cancer treatment. Utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies, Juno engineers T cells to target and eliminate cancer cells. The company's product pipeline includes several promising candidates, such as JCAR017, in Phase I/II trials for relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, as well as JCAR018 for pediatric patients with CD22-positive cancers. Other candidates target various malignancies, including neuroblastoma, lung cancer, ovarian cancer, and glioblastoma. Juno collaborates with leading cancer research institutions to advance its therapies and was founded in 2013, headquartered in Seattle, Washington. In 2018, Juno became a subsidiary of Bristol-Myers Squibb Company.

Faraday Pharmaceuticals, established in 2014 and headquartered in Seattle, Washington, is an early-stage biopharmaceutical company dedicated to developing innovative therapies targeting ischemia-reperfusion injury. The company's proprietary pipeline comprises liquid formulations of reduced nonmetal gaseous elements, licensed from the lab of Dr. Mark Roth at Fred Hutchinson Cancer Center. Faraday Pharmaceuticals aims to create elemental reducing agents that can improve patient outcomes by simplifying the treatment of critical care illnesses like reperfusion injury following ST elevation myocardial infarction.

SAGE Therapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, dedicated to developing innovative treatments for central nervous system (CNS) disorders. The company's lead product, ZULRESSO, is an intravenous formulation of brexanolone specifically designed for the treatment of postpartum depression. SAGE Therapeutics is advancing a diverse product pipeline, including SAGE-217, a novel neuroactive steroid in Phase III trials for various depressive disorders and anxiety, and SAGE-324, currently in Phase II trials for essential tremors and other neurological conditions. Additionally, SAGE-718, an oxysterol-based positive allosteric modulator, has completed Phase I trials targeting multiple CNS-related disorders. The company also explores other compounds, such as SAGE-904 and SAGE-689. SAGE Therapeutics has established strategic collaborations with Shionogi & Co., Ltd. and Biogen Inc. for the development and commercialization of its key product candidates, emphasizing its commitment to addressing the challenges of brain health.

Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company dedicated to developing innovative treatments for cardiopulmonary diseases. Headquartered in Warren, New Jersey, the company focuses on its proprietary INOpulse platform, which delivers pulsatile nitric oxide, targeting various forms of pulmonary hypertension. Bellerophon is advancing multiple product candidates through clinical trials, including treatments for pulmonary hypertension associated with interstitial lung disease and chronic obstructive pulmonary disease, as well as other conditions such as sarcoidosis and chronic thromboembolic pulmonary hypertension. Additionally, Bellerophon is exploring a bioabsorbable cardiac matrix device aimed at preventing cardiac remodeling after myocardial infarction, currently undergoing a feasibility clinical trial in the European Union. Founded in 2009 and previously known as Ikaria Development LLC, Bellerophon Therapeutics aims to address significant unmet medical needs in the cardiopulmonary space.

Juno Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing innovative cell-based immunotherapies for cancer treatment. Utilizing chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies, Juno engineers T cells to target and eliminate cancer cells. The company's product pipeline includes several promising candidates, such as JCAR017, in Phase I/II trials for relapsed or refractory non-Hodgkin lymphoma and acute lymphoblastic leukemia, as well as JCAR018 for pediatric patients with CD22-positive cancers. Other candidates target various malignancies, including neuroblastoma, lung cancer, ovarian cancer, and glioblastoma. Juno collaborates with leading cancer research institutions to advance its therapies and was founded in 2013, headquartered in Seattle, Washington. In 2018, Juno became a subsidiary of Bristol-Myers Squibb Company.